GALT: Meets FDA
Galectin Therapeutics announces positive Type C meeting with the FDA for Belapectin in patients with MASH cirrhosis and portal hypertension
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.